drugset / Trial / NCT01996761

Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke

NCT01996761

Phase 4 Completed 71 enrolled Samsung Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study, E-COMPASS is a phase IV clinical trial designed as a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. This study will enroll 75 subacute stroke patients with unilateral motor dysfunction. Primary objective is to demonstrate the efficacy of porcine brain peptide to improve motor recovery measured by the improvement ratio of Fugl-Meyer assessment ((score of FMA after 3 weeks - score of FMA at baseline) / score of FMA at baseline) in patients with subacute stroke.

Timeline

Start
2011-01
Primary completion
2014-01
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cerebrolysin Peptide 30 ml

Indications

No indication recorded.